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Poor graft function (PGF) is characterized by pancytopenia and a hypoplastic marrow, with complete donor
chimerism, usually without severe graft-versus-host disease (GVHD). We report 41 patients with PGF, treated
with granulocyte colony-stimulating factoremobilized CD34 selected cells, at a median interval from
transplant of 140 days, without conditioning and without GVHD prophylaxis. Donors were HLA matched
siblings (n ¼ 12), unrelated donors (n ¼ 18), or mismatched family members (n ¼ 11). The median number of
infused CD34þ cells was 3.4  106/kg. The rate of trilineage recovery was 75%: 83% for HLA matched siblings
and 72% for unrelated and mismatched family members (P ¼ .3). The cumulative incidence of acute grade II
GVHD was 15%, and no patient developed de novo chronic GVHD. The actuarial 3-year survival is 63%: 76%
and 25% for patients with or without trilineage recovery. These data conﬁrm the role of CD34þ selected cells
from the same donor in the treatment of PGF and warrant the request for a second donation also when the
donor is unrelated.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Poor graft function (PGF) is a severe complication that
occurs after allogeneic hematopoietic stem cell trans-
plantation (HSCT) in 5% to 27% of patients [1-3]. Several
factors have been shown to predict PGF, such as donor type,
HLA matching, ABO incompatibility, cell dose, stem cell
source, graft-versus-host disease (GVHD), viral infections,
intensity of conditioning regimen, and the use of myelotoxic
agent, such as ganciclovir [2-5]. The pathogenesis of PGF is
probably multifactorial and includes immunologic issues as
well as abnormalities in bone marrow microenvironment,
number of progenitor cells, and type of the underlying dis-
ease [2-6].
PGF is deﬁned as severe cytopenia of at least 2 cell lines
and/or transfusion requirement in the presence of a hypo-
plastic/aplastic bonemarrow, with full donor chimerism, and
in the absence of severe acute or chronic GVHD [7,8] or
relapse [1,2]. PGF should not be mistaken for rejection, in
which chimerism is mixed or 100% host. Primary PGF occurs
early after transplant, whereas secondary PGF occurs after
the patient has experienced a certain degree of hematologic
recovery. PGF may be treated with granulocyte colony-
stimulating factor (G-CSF) [9] or with G-CSF and thrombo-
poietin, as recently reported in 3 patients [10]. However, a
signiﬁcant proportion of patients do not respond to growth
factors and remain cytopenic. In this cohort of poor/edgments on page 1443.
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14.05.016nonresponders, an efﬁcient treatment option is the infusion
of donor CD34þ selected peripheral blood stem cells (PBSCs)
without further conditioning [1]. In this report we update
our previous experience and report 41 patients with PGF
treated with CD34þ selected hematopoietic progenitors.METHODS
Patients
We studied 41 patients with secondary PGF after allogeneic HSCT who
received a boost of CD34þ selected PBSCs without prior conditioning and
without GVHD prophylaxis at median interval of 140 days from the ﬁrst
transplant. Clinical characteristics are shown in Table 1.
At the time of the CD34 infusion, the median neutrophil count was
1.44  106/L (range, 0 to 3.2), the median platelet count was 21  109/L
(range, 5 to 193), and the median hemoglobin concentration was 8.9 g/dL
(range, 6.9 to 11). We infused a median number of 3.45  106/kg.
CD34þ selected cells (range, .05 to 22.5). The median age of patients was
37 years (range, 18 to 62) (Table 1).Poor Graft Function
We deﬁned PGF as follows: (1) 2 or 4 cytopenic lines for at least 2
consecutive weeks beyond day þ14 from allogeneic HSCT (hemoglobin
<10 g/dL), neutrophil count <1.0  109/L, platelet count <30  109/L and/or
(2) transfusion requirement, in the presence of a hypoplastic-aplastic bone
marrow, with full donor chimerism and (3) without grades III to IV acute
GVHD [7,8] and (4) in the absence of relapse [1].Boost Infusion
G-CSF mobilized peripheral blood cells were collected by standard
procedures from the original donor. CD34þ selection was performed by
immune-magnetic separation using the CliniMACS Device (Miltenyi Biotec,
Bologna Italy). This device allows depletion of 3 log of T cells: the ﬁnal
product contained between 2.5  103 and 10  103 CD3þ cells/kg of a
recipient’s body weight. CD34þ selected cells were infused intravenously,
without conditioning regimen and without GVHD prophylaxis (Table 1).Chimerism
Chimerism was assessed on marrow cells using the microsatellite
technique (short-tandem-repeat PCR) [11].
Table 1
Clinical Characteristics of 41 Patients Receiving Boost CD34þ Selected Cells
Characteristic Value
No. of patients 41
Conditioning before CD34þ PB None
GVHD prophylaxis before CD34þ PB None
Median age, yr (range) 37 (18-62)
Diagnosis ALL n ¼ 7, AML n ¼ 8, CML
n ¼ 8, MFI
n ¼ 4, NHL n ¼ 6, SAA n ¼ 4
Donor type HLA id n ¼ 12, MUD n ¼ 18,
family mm n ¼ 11
Source BM n ¼ 32, PB n ¼ 9
Conditioning regimen at ﬁrst HSCT Myeloablative, n ¼ 25 (58%)
CMV before CD34þ cell infusion 30 (73%)
TMA before CD34þ cell infusion 8 (19%)
GVHD before CD34 cell infusion Grade 0/I n ¼ 36 (78%);
grade II n ¼ 5 (12%)
Conditioning regimen before CD34þ
cells
None
GVHD prophylaxis after CD34þ cells None
Median CD34þ infused (range) 3.45  106/kg (.05-22.5)
Median CD3þ cells infused (range) 5.6  103/kg (2.5-10)
Median days from ﬁrst allogeneic
HSCT (range)
140 d (48-374)
Median platelet count at CD34þ
infusion (range)
21  109/L (5-193)
Median neutrophil count at CD34þ
infusion (range)
1.44  109/L (0-3.2)
Median Hb level at CD34þ infusion
(range)
8.9 g/dL (6.9-11)
Acute GVHD after infusion Grade II-III n ¼ 9, grade IV
none
Median follow-up (range) 1245 d (94-4151)
PB indicates peripheral blood; ALL, acute lymphoblastic leukemia; AML,
acute myeloid leukemia; CML, chronic myeloid leukemia; MFI, myeloﬁ-
brosis idiopathic; NHL, non-Hodgkin lymphoma; SAA, severe aplastic ane-
mia; MUD, matched unrelated donor; family mm, family mismatch; BM,
bone marrow; CMV, cytomegalovirus; Hb, hemoglobin.
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Complete hematologic response or trilineage recovery was deﬁned as
achieving hemoglobin >10 g/dL, absolute neutrophil count >1  109/L, and
platelets >100  109/L. Partial response or partial recovery was deﬁned as
transfusion independence, without a complete hematologic recovery.
Statistical Analysis
The NCSS 9 package (Kaysville, UT) was used for the chi-square tables,
cumulative incidence (CI) rates, Student t-test, and Mann-Whitney test.
When calculating the CI of trilineage recovery, the competing risk was death
due to any cause. When calculating the CI of nonrelapse mortality, the
competing risk was relapse-related mortality.
RESULTS
Graft-versus-Host Disease
The CI of acute GVHD grade II after CD34 infusionwas 15%
(Figure 1A). Three patients had moderate chronic GVHD
before and after CD34þ cell infusion.
Response
The CI of trilineage recovery was 75% (Figure 1B). A partial
response was seen in 3 patients, with an overall response
rate of 83% (34/41 patients); 7 of 41 patients (17%) were
considered nonresponders. The median time for complete
hematologic recovery to occur was 101 days (range, 13 to
994) from CD34þ PBSC boost infusions (Figure 1B).
The median platelet count on days 0, þ30, þ60, and þ100
from CD34þ cell infusions were as follows, respectively:
21  109/L (range, 5 to 193), 51  109/L (range, 10 to 246),
65  109/L (range, 5 to 304), and 82  109/L (range, 1 to 274).We could ﬁnd no association between trilineage recovery
and clinical characteristics such as age, sex, underlying
diagnosis, and disease status before transplant. Similarly, the
dose of CD34þ PBSCs infused (<3.3 versus 3.3  106/kg)
appeared to have no impact on hematologic recovery (78%
versus 72%, respectively, P ¼ .6). There was a nonsigniﬁcant
trend for a greater chance of trilineage recovery in siblings
(83%) as compared with unrelated and family mismatched
donors (72%) (P ¼ .3); the timing was nearly identical (103
and 105 days, respectively). Patients who received a mye-
loablative conditioning regimen at ﬁrst transplant had a
borderline greater chance of trilineage recovery (87% versus
61%, P ¼ .06).
Survival
With a median follow-up of 1245 days (range, 94 to 4151)
from the infusion of CD34þ cells, 28 patients (68%) survived
disease free, all having achieved a durable trilineage recov-
ery. The current actuarial 3-year survival rate is 63%
(Figure 1C).
There was a strong impact, in univariate analysis, of
hematologic recovery on survival: 76% versus 25% for
patients with or without trilineage recovery (P < .0001)
(Figure 1D). In multivariate analysis, trilineage recovery was
the strongest predictor (relative risk, .01; P¼ .0001) followed
by sibling donors (relative risk, .13; P ¼ .03).
Thirteen patients died. Relapse-related death was diag-
nosed in 8 of 41 patients (19%) and nonrelapse mortality in 5
of 41 patients (12%): 2 due to pre-existing chronic GVHD
and 3 to infections, in patients who did not recover
hematopoiesis.
DISCUSSION
We report 41 patients who received infusion of CD34þ
selected PBSCs from the original donors, without condition-
ing regimen and without GVHD prophylaxis, for the treat-
ment of PGF. The procedure is safe, with a low risk of grade II
acute GVHD (15%) and no grades III to IV or de novo chronic
GVHD: 3 patients hadmoderate chronic GVHD, which did not
worsen after infusion of CD34þ cells. The primary objective of
intervention in patients who are cytopenic, transfusion
dependent, and often infected is a lack of severe side effects
and of GVHD, despite the lack of GVHD prophylaxis. It should
be noted that all patients were infused without conditioning
regimen, due to the demonstration of full donor chimerism,
and this may have been a relevant factor to reduce side effects
to a minimum, together with a very low number of infused
CD3þ cells, with a median of less than 10  103/kg. The latter
observation is in keeping with the efﬁcacy of the separation
device currently used worldwide.
In a previous study we reported 20 patients, with 75%
trilineage recovery [1]. In the present study we included 21
newly treated patients and updated the 20 previously
reported: the median follow-up is now 1245 days (range, 94
to 4151). The overall CI of trilineage recovery is 75%, therefore
conﬁrming, in this larger series of patients, our previous
results. Hematologic recovery was durable in all patients we
evaluated so far. Two recent reports have addressed the issue
of PGF and its treatment with CD34þ selected donor stem
cells [12,13], showing 50 patients with a chance of hemato-
logic improvement of, respectively, 72% and 81%.
The overall 3-year actuarial survival, in our study, was
63%, with a signiﬁcant impact on survival of hematologic
recovery: 76% for patients in complete remission and 25% for
Table 2
Studies with CD34þ Boost Infusions in Patients with PGF
Askaa et al.
2014 [12]
Klyuchnikov
et al. 2014 [13]
This
Study
Total or
Average
Year of publication 2014 2014 2014
No. of patients 18 32 41 91
Myeloﬁbrosis 6 14 4 24 (26%)
Interval transplant boost 113 150 140 134
CD34þ cell dose  106/kg 3,7 3,4 3,55
CD3þ cell dose  103/kg 11 9 5.6 8.5
Hematologic recovery 72% 81% 75% 76%
Stable hematologic
recovery
Yes Yes Yes Yes
GVHD grades III-IV 2 4 0 6 (7%)
De novo chronic 0 0 0 0
Median follow-up, d 1072 900 1245 1072.5
Actuarial 3-yr survival 40% 45% 63% 49%
Figure 1. (A). CI of acute GVHD grade II; no patient had grades III to IV. (B) CI of trilineage recovery. (C) Actuarial survival. (D) Actuarial survival in patients stratiﬁed
for trilineage response: a signiﬁcant advantage for patients with trilineage recovery.
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transfusion independency without trilineage recovery)
(P < .0001). In multivariate analysis this was also the stron-
gest predictor of survival, followed by the use of CD34þ cells
from HLA identical sibling donors. We did not ﬁnd an
association of trilineage recovery with the underlying
disease, HLA matching, donor recipient gender and age, ABO
compatibility, or history of previous GVHD. In addition in our
cohort, the probability of recovery was not inﬂuenced by the
dose of CD34þ cells, ranging from .05 to 22  106/kg;
recovery could also be seen with a low dose of CD34þ cells.
The median time to trilineage recovery from CD34þ boost
infusion was 101 days, although platelet counts started to
rise on day þ30 and progressively increased thereafter,
similar to that recently described [12,13]. The relatively long
time to achieve complete trilineage recovery may be due to
the complex nature of these patients, often with multiple
infections and cytotoxic treatment. Indeed, the large
majority (73%) had cytomegalovirys reactivation and were
therefore treated with ganciclovir and/or foscarnet before
CD34þ cell infusion, and thus at the time of PGF. In addition,
almost 20% had a diagnosis of transplant-associated micro-
angiopathy preinfusion; transplant-associated micro-
angiopathy is known to cause prolonged cytopenia.When pooling together 2 recent reports [12,13] with the
present study (Table 2), there are 91 patients with PGF
treated with boost CD34þwithout conditioning andwithout
GVHD prophylaxis exhibiting some strong similarities. First,
there was a high proportion of patients with myeloﬁbrosis.
Although we are unaware of the total denominator, it is
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patients with myeloﬁbrosis. Indeed, at our own center,
during the time interval when our 41 patients were diag-
nosed with PGF, the proportion of myeloﬁbrosis of all allo-
geneic transplants was 7% (81/1206), suggesting that
myeloﬁbrosis is at high risk for PGF patients, as already
suggested by others. The second similarity is the almost
identical interval between transplant and boost infusion,
with a very narrow range (113 to 140 days), suggesting we
are reporting the same type of PGF. The number of infused
CD34þ cells is also almost identical, as well as the lack of
correlation between cell dose and recovery. Of interest, once
hematologic recovery has occurred, it was deﬁned as stable
in all 3 studies. The rate of acute grades III to IV GVHD is
somewhat higher in 2 studies, but we are talking of small
numbers. We did not calculate the average time to hema-
tologic recovery, only because in 1 study it was given as
initial recovery and in our study as full recovery; however,
the overall proportion of patients showing recovery is
almost identical.
These data bring additional evidence for the effectiveness
of CD34þ selected cells from G-CSF mobilized peripheral
blood of the original donor in patients with PGF. The low rate
of GVHD in the absence of GVHD prophylaxis is reassuring.
Finally, the high rate of trilineage recovery also with CD34þ
cells from unrelated donors may be relevant for registry
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